Takeda Zasocitinib Shows Strong Phase 3 Psoriasis Data
OSAKA, Japan and CAMBRIDGE, Mass., March 28, 2026 Takeda announced positive results from its Phase 3 LATITUDE clinical trials...
Dermatology
Advertisement
Celldex Barzolvolimab Shows Strong Phase 2 Urticaria Data
Hampton, N.J., USA | March 27, 2026 Celldex Therapeutics reported compelling results from Phase 2 clinical trials of barzolvolimab,...
Dupixent Approved in Japan for Rare Skin Disease
PARIS, FRANCE & TARRYTOWN, NEW YORK, USA | March 24, 2026 Sanofi and Regeneron have announced that Japan’s Ministry...
Turn Therapeutics Secures $25M for Skin Pipeline
LOS ANGELES, USA | March 24, 2026 Turn Therapeutics, Inc., a clinical-stage dermatology-focused biotechnology company, has announced a strategic...
Nektar Therapeutics Reports Phase 2b Rezpegaldesleukin Data
San Francisco, California, USA | March 20, 2026 Nektar Therapeutics has announced that Phase 2b clinical data for rezpegaldesleukin,...
Advertisements
Ameluz® PDT Phase 3 Trial Meets Primary Endpoint
WOBURN, Mass., Feb. 9, 2026 — Biofrontera Inc. announced positive top-line results from its multicenter Phase 3 clinical trial...
Legacy Advances Cinainu into Phase 3 Alopecia Areata Trial
LAUSANNE, Switzerland | January 6, 2026 — Legacy Healthcare announced that it will advance its topical botanical drug candidate,...
AAD Supports FDA Plan to Approve New Sunscreen Ingredient
WASHINGTON, D.C., December 11, 2025 — The American Academy of Dermatology Association (AAD) issued a formal statement supporting the...
Mabwell’s 9MW3011 Achieves Positive Phase III Results in Moderate-to-Severe Plaque Psoriasis
SHANGHAI, CHINA – November 11, 2025 — Mabwell (688062.SH), an innovative biopharmaceutical company specializing in biologics for major diseases,...
Novartis wins FDA approval for first oral BTKi in chronic urticaria
EAST HANOVER, N.J., Sept. 30, 2025 – Novartis today announced that the U.S. Food and Drug Administration (FDA) has...
Advertisement
